Pear Therapeutics to Participate in the Jefferies Healthcare Conference

Rhea-AI Summary

Pear Therapeutics, Inc. (Nasdaq: PEAR) announced its participation in the Jefferies Healthcare Conference scheduled for June 8-10, 2022, in New York City. The CFO and COO, Chris Guiffre, will present on June 10, at 9:30 AM EDT. Investors can arrange one-on-one meetings through Jefferies. A live audio webcast of the presentation will be available here and can be accessed later for 30 days on Pear’s website. Pear specializes in prescription digital therapeutics (PDTs) for various conditions.

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Jefferies Healthcare Conference taking place June 8-10 in New York, New York. Chris Guiffre, Chief Financial Officer and Chief Operating Officer, will give a corporate presentation on June 10, 2022, at 9:30 AM EDT.

Pear will be available for one-on-one meetings during the conference. Investors interested in meeting with Pear at the conference should contact their Jefferies representative.

A live audio webcast of the presentation can be accessed by clicking here and will be made available in the Investors section of Pear’s website at www.peartherapeutics.com. A replay of the webcast will be available on Pear’s website for up to 30 days following the live presentation.

About Pear Therapeutics
Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005569/en/

Media and Investors:

Meara Murphy

Senior Director, Corporate Communications

meara.murphy@peartherapeutics.com

Source: Pear Therapeutics, Inc

FAQ

When is Pear Therapeutics participating in the Jefferies Healthcare Conference?

Pear Therapeutics will participate in the Jefferies Healthcare Conference from June 8-10, 2022.

What time will Pear's presentation at the conference occur?

The presentation by Pear's CFO Chris Guiffre is scheduled for June 10, 2022, at 9:30 AM EDT.

How can investors meet with Pear Therapeutics during the conference?

Investors interested in meeting with Pear Therapeutics can contact their Jefferies representative.

Where can I access the live audio webcast of Pear's presentation?

The live audio webcast can be accessed here and will also be available on Pear's website.

What is the main focus of Pear Therapeutics?

Pear Therapeutics focuses on developing software-based medicines, known as prescription digital therapeutics (PDTs).